An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan

References

• Kubota K, Kamijima Y, Sato T, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015;5(1):e006450–e006450.
   PubMed Web of Science ®Google Scholar
• Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866–873.
   PubMed Web of Science ®Google Scholar
• Fortune DG, Richards HL, Griffiths CE. Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin. 2005;23(4):681–694.
   PubMed Web of Science ®Google Scholar
• Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3):401–407.
   PubMed Web of Science ®Google Scholar
• Moller AH, Erntoft S, Vinding GR, et al. A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values. Patient Relat Outcome Meas. 2015;6:167–177.
   PubMedGoogle Scholar
• Hayashi M, Saeki H, Ito T, et al. Impact of disease severity on work productivity and activity impairment in Japanese patients with psoriasis. J Dermatol Sci. 2013;72(2):188–191.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Zhao Y, Gilloteau I, et al. Higher psoriasis skin clearance is associated with lower annual indirect costs in the United States: a post hoc analysis from the CLEAR study. J Manag Care Spec Pharm. 2018;24(7):617–622.
   PubMed Web of Science ®Google Scholar
• Feldman SR. Treatment of psoriasis in adults; 2019. [cited 2019 Dec 9]. Available from: https://www.uptodate.com/contents/treatment-of-psoriasis-in-adults/
   Google Scholar
• Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2017;12:CD011535.
   PubMed Web of Science ®Google Scholar
• Pharmaceuticals and Medical Devices Agency. List of approved products. [cited 2019. Dec 1]. Available from: https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html
   Google Scholar
• Japanese Dermatological Association. [Japanese guidance for use of biologics for psoriasis (the 2018 version)]; 2019. [cited 2019 Nov 11]. Japanese. Available from: https://www.dermatol.or.jp/uploads/uploads/files/news/J20190219_gaid.pdf
   Google Scholar
• Ohtsuki M, Terui T, Ozawa A, et al. Japanese guidance for use of biologics for psoriasis (the 2013 version). J Dermatol. 2013;40(9):683–695.
   PubMed Web of Science ®Google Scholar
• Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015;136(1):116–124.e7.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–661.
   PubMed Web of Science ®Google Scholar
• Reich K, Gooderham M, Thaci D, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576–586.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Gooderham M, et al. Risankizumab efficacy/safety in moderate-to-severe plaque psoriasis: 16-week results from IMMhance. Acta Derm Venereol. 2018;98(suppl 219):30.
   Google Scholar
• Pharmaceuticals and Medical Devices Agency. List of approved products. [cited 2019 Dec 1]. Available from: https://www.pmda.go.jp/files/000229856.pdf
   Google Scholar
• Takahashi H, Satoh K, Takagi A, et al. Economic burden of psoriatic patients in Japan: analysis from a single outpatient clinic. J Dermatol. 2017;44(9):1024–1026.
   PubMed Web of Science ®Google Scholar
• Takura T. An evaluation of clinical economics and cases of cost-effectiveness. Intern Med. 2018;57(9):1191–1200.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Satoh K, Takagi A, et al. Cost-efficacy and pharmacoeconomics of psoriatic patients in Japan: analysis from a single outpatient clinic. J Dermatol. 2019;46(6):478–481.
   PubMed Web of Science ®Google Scholar
• Igarashi A, Kuwabara H, Fahrbach K, et al. Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan. J Dermatolog Treat. 2013;24(5):351–355.
   PubMed Web of Science ®Google Scholar
• Igarashi A, Igarashi A, Graham CN, et al. Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective. J Med Econ. 2018;22(1):7–15.
   Web of Science ®Google Scholar
• Fukuda T, Shiroiwa T. Application of economic evaluation of pharmaceuticals and medical devices in Japan. J Natl Inst Public Health. 2019;68(1):27–33.
   Google Scholar
• Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health (C2H). Guideline for preparing cost-effectiveness evaluation to the Central Social Insurance Medical Council: version 2.0; 2019. [cited 2019 Nov 11]. Available from: https://c2h.niph.go.jp/tools/guideline/guideline_en.pdf
   Google Scholar
• Ohkusa Y, Sugawara T. Research for willingness to pay for one QALY gain. J Health Care Soc. 2006;16(2):157–165. Japanese.
   Google Scholar
• Shiroiwa T, Sung Y, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010;19(4):422–437.
   PubMed Web of Science ®Google Scholar
• Tada Y, Ishii K, Kimura J, et al. Patient preference for biologic treatments of psoriasis in Japan. J Dermatol. 2019;46(6):466–477.
   PubMed Web of Science ®Google Scholar
• Saeki H, Terui T, Morita A, et al. Japanese guidance for use of biologics for psoriasis (the 2019 version). J Dermatol. 2020;47(3):201–222. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal; 2013. [cited 2019 Nov 11]. Available from: https://www.nice.org.uk/process/pmg9/chapter/foreword
   Google Scholar
• Ohtsuki M, Fujita H, Watanabe M, et al. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase 2/3 trial. J Dermatol. 2019;46(8):686–694.
   PubMed Web of Science ®Google Scholar
• National Institute of Health and Care Excellence. NICE pathway: psoriasis; 2017. [cited 2017 Sep]. Available from: http://pathways.nice.org.uk/pathways/psoriasis
   Google Scholar
• Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258.
   PubMed Web of Science ®Google Scholar
• Shear NH, Joshi AD, Zhao J, et al. Comparison of safety outcomes for treatments of moderate to severe plaque psoriasis through a network meta-analysis. Poster presented at the 24th World Congress of Dermatology, June 2019. Milan, Italy.
   Google Scholar
• Warren RB, Smith CH, Yiu ZZ, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632–2640.
   PubMed Web of Science ®Google Scholar
• Ministry of Heath, Labour and Welfare. National life tables; 2017. [cited 2019 Apr 15]. Available from: https://www.mhlw.go.jp/toukei/saikin/hw/life/life17/xls/life17-12.xls
   Google Scholar
• Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess. 2006;10(46):1–258.
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Labour and Welfare. 薬価基準収載品目リスト及び後発医薬品に関する情報について（令和元年9月30日まで）[List of drugs and generics by 30 Sep 2019]; 2019. [cited 2019 Dec 23]. Japanese. Available from: https://www.mhlw.go.jp/topics/2018/04/tp20180401-01.html
   Google Scholar
• Ministry of Heath, Labour and Welfare. 平成30年度診療報酬改定について [2018 Medical Treatment Fee Revision]; 2019. [cited 2019 May 31]. Japanese. Available from: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000188411.html
   Google Scholar
• Electronic Medicines Compendium. Summary of product characteristics: cosentyx 150 mg solution for injection in pre-filled syringe and pre-filled pen. [cited 2017 Jul]. Available from: https://www.medicines.org.uk/emc/print-document?documentId=29848
   Google Scholar
• Electronic Medicines Compendium. Summary of product characteristics: humira 40 mg/0.4 ml pre-filled syringe and pre-filled pen. [cited 2017 Jul]. Available from: https://www.medicines.org.uk/emc/print-document?documentId=31860
   Google Scholar
• Electronic Medicines Compendium. Summary of product characteristics: stelara 45 mg and 90mg, solution for injection (vials) and solution for injection in pre filled syringe. [cited 2017 Jul]. Available from: https://www.medicines.org.uk/emc/print-document?documentId=32569
   Google Scholar
• Langley RE, Lebwohl M, Reich K, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–356.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–1328.
   PubMed Web of Science ®Google Scholar
• Dixon W, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54(8):2368–2376.
   PubMed Web of Science ®Google Scholar
• Reich K, Mrowietz U, Radtke M, et al. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest. Arch Dermatol Res. 2015;307(10):875–883.
   PubMed Web of Science ®Google Scholar
• Tokunaga M, Nakane N. Study on outpatient’s waiting time during all phases of medical consultation. J Jpn Soc Health Care Manag. 2006;7(3):434–437.
   Google Scholar
• Ministry of Heath, Labour and Welfare. 平成8年受療行動調査の概要 [Patient’s behavior survey]; 1996. [cited 2019 Jul 9]. Japanese. Available from: https://www.mhlw.go.jp/www1/toukei/h8jyuryo_8/01-03.html
   Google Scholar
• Guide to Japan’s National Health Insurance (NHI) System; 2017. [cited 2019 Dec 6]. Available from: https://yosida.com/forms/nationalins.pdf
   Google Scholar
• Ministry of Health, Labour and Welfare. 高額療養費制度の見直しについて [Revision of high-cost medical expense benefit]. 2016. [cited 2019 Dec 23]. Japanese. Available from: https://www.mhlw.go.jp/file/05-Shingikai-12601000-Seisakutoukatsukan-Sanjikanshitsu_Shakaihoshoutantou/0000138069.pdf
   Google Scholar
• Bank of Japan. Standard foreign exchange rates and arbitrage foreign exchange rates (applicable in May 2019). [cited 2020 Mar 3]. Japanese. Available from: https://www.boj.or.jp/about/services/tame/tame_rate/kijun/kiju1905.htm/
   Google Scholar
• Bertram MY, Lauer JA, De Joncheere K, et al. Cost–effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94(12):925–930.
   PubMed Web of Science ®Google Scholar
• The World Bank. GDP per capita (constant LCU) – Japan. World Bank national accounts data, and OECD National Accounts data files; 2018. [cited 2019 Dec 18]. Available from: https://data.worldbank.org/indicator/NY.GDP.PCAP.KN?locations=JP
   Google Scholar
• Vanderpuye-Orgle J, Zhao Y, Lu J, et al. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol. 2015;72(6):961–967.e5.
   PubMed Web of Science ®Google Scholar
• Fowler JF, Duh MS, Rovba L, et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol. 2008;59(5):772–780.
   PubMed Web of Science ®Google Scholar
• Bilvick Tai B, Bae YH, Le QA. A systematic review of health economic evaluation studies using the Patient's Perspective. Value Health. 2016;19(6):903–908.
   PubMed Web of Science ®Google Scholar
• Garrison LP, Jr., Pauly MV, Willke RJ, et al. An overview of value, perspective, and decision context-a health economics approach: an ISPOR Special Task Force report [2]. Value Health. 2018;21(2):124–130.
   PubMed Web of Science ®Google Scholar